Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shanghai Junshi Biosciences Co. Ltd. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 7 distinct art units, showing complete distribution across both examiner and art-unit assignments in the reported docket.
STEPHENS, AMELIA CAROLE is the busiest examiner, with 1 pending matter. That figure confirms that no examiner carries a larger identified concentration of the pending work.
The profile favors decentralized prosecution management. Counsel should maintain a common technical and claim framework where appropriate, but prepare each response around its individual examiner and art-unit context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 4 (57%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297983 | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy | ABBAS, SYED JARAR | 15d |
| 18869686 | BIOMARKERS AND METHODS FOR TREATING NSCLC | STEPHENS, AMELIA CAROLE | — |
| 18562353 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER | HAMA, JOANNE | — |
| 18043204 | USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA | BERHANE, SELAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18869686 | BIOMARKERS AND METHODS FOR TREATING NSCLC | STEPHENS, AMELIA CAROLE | — |
| 18686817 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CHATTIN, AMY MARIE | — |
| 18562353 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER | HAMA, JOANNE | — |
| 18556885 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER | LU, CHENG | — |
| 18043204 | USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA | BERHANE, SELAM | — |
| 17604058 | USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICAMENT FOR TREATING SOLID TUMORS | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1643 | 1 |
| 1647 | 1 |
| 1642 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18869686 | BIOMARKERS AND METHODS FOR TREATING NSCLC | STEPHENS, AMELIA CAROLE | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18686817 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CHATTIN, AMY MARIE | 1643 | §112DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18562353 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER | HAMA, JOANNE | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18556885 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER | LU, CHENG | 1642 | §103§112DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18297983 | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy | ABBAS, SYED JARAR | 1674 | §102§103DP | Non-Final OA | 15d | Pending | Apr 10, 2023 |
| 18043204 | USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA | BERHANE, SELAM | 1675 | §103§112 | Final Rejection | — | Pending | Feb 27, 2023 |
| 17604058 | USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICAMENT FOR TREATING SOLID TUMORS | SALMON, KATHERINE D | 1682 | §112 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Junshi Biosciences Co. Ltd. has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Amelia Carole Stephens has the most, with 1 of Shanghai Junshi Biosciences Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
